このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。英語版ソーステキスト用。

The Epidemiology of Ventricular Assist Device-Related Infections

2011年11月15日更新者：Icahn School of Medicine at Mount Sinai

Infections often occur after ventricular assist devices (VADs) are placed. These infections can be very serious. The goal of this study is to understand why these infections occur. Bacteria (germs) normally live on our skin and in our noses. After surgery, they can infect the VAD. The investigators will collect cultures of your skin and nose before and after surgery. The investigators will compare these bacteria to bacteria that cause infections. Their genes will be compared to see which ones help the bacteria cause infection.

調査の概要

状態

完了

条件

うっ血性心不全

詳細な説明

Infections are one of the most serious of ventricular assist device (VAD) related complications. Many of these infections are associated with significant patient morbidity and mortality. Diagnosis of these infections is often difficult due to the complicated nature of the patient's medical problems, the need for rapid institution of empiric antibiotic therapy and the lack of established criteria that define infection. Staphylococci are among the most common causes of VAD infections. The basis for this high incidence is not well understood but is believed to be in part due to inoculation of staphylococcal commensal flora into wound sites at the time of surgery or thereafter. The goals of this observational study are to develop a better understanding of the pathogenesis and epidemiology of Staphylococcus aureus and epidermidis-VAD infections as well as to develop a set of criteria that can be used to help diagnose the presence or absence of a VAD related infection.

This is a prospective, multi-center, observational study to identify risk factors associated with the development of VAD-related infections. Patients will be followed for up to one year following VAD implantation, time of death or transplantation, whichever comes first. There will be no randomization for this observational study.

研究の種類

観察的

入学 (実際)

150

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

アメリカ
- Alabama
  - Birmingham、Alabama、アメリカ、35294
    - University of Alabama at Birmingham
- California
  - San Diego、California、アメリカ、92123
    - Sharp Memorial Hospital
- Illinois
  - Oak Lawn、Illinois、アメリカ、60453
    - Advocate Christ Medical Center
- Kentucky
  - Louisville、Kentucky、アメリカ、40202
    - Jewish Hospital
- Michigan
  - Ann Arbor、Michigan、アメリカ、48109
    - University of Michigan
- Minnesota
  - Minneapolis、Minnesota、アメリカ、55455
    - University of Minnesota
- New York
  - Bronx、New York、アメリカ、10467
    - Montefiore Medical Center
  - New York、New York、アメリカ、10032
    - Columbia Presbyterian Medical Center
- Pennsylvania
  - Philadelphia、Pennsylvania、アメリカ、19104
    - Hospital of the University of Pennsylvania
- Utah
  - Salt Lake City、Utah、アメリカ、84143
    - LDS Hospital
- Washington
  - Spokane、Washington、アメリカ、99204
    - Sacred Heart Medical Center
- Wisconsin
  - Madison、Wisconsin、アメリカ、53792
    - University of Wisconsin Hospital
  - Milwaukee、Wisconsin、アメリカ、53215
    - St. Luke's Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Patients with end-stage heart failure who demonstrate the need for intermediate or long-term support with a VAD.

説明

Inclusion Criteria:

Age greater than or equal to 18 years.
Approved by the institution's heart failure/transplant committee for VAD implantation, either as a bridge to cardiac transplantation or for destination therapy for end-stage heart failure.
Signed informed consent, release of medical information, and HIPAA forms.
Expectation of compliance with protocol procedures and study visit schedule.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

グループ/コホートの数

コホートと介入

グループ/コホート
Study Population 150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.

この研究は何を測定していますか？

主要な結果の測定

結果測定	メジャーの説明	時間枠
The incidence of suspected infections, characterized by infecting organism and location. 時間枠：Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.	The primary goal is to collect information that describes infections in patients receiving LVADs.	Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.

二次結果の測定

結果測定	メジャーの説明	時間枠
Collect and quantify culture results for suspected infections and the secondary manifestations of infection 時間枠：Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.	Bacteria normally live on our skin and in our noses.After surgery, they can infect the VAD. We will collect cultures before and after surgery and compare these bacteria to bacteria that cause infections.Their genes will be compared to see which ones help the bacteria cause infection. We hope this will help develop new ways to help prevent VAD infections.	Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
Develop Guidelines to properly diagnose VAD infections 時間枠：Up to one year following VAD implantation, time of death or transplantation, whichever comes first.	Information will be collected on patient's medical condition after surgery including blood tests to help determine if an infection is present.	Up to one year following VAD implantation, time of death or transplantation, whichever comes first.
Costs (direct) 時間枠：Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.	The value of all resources that are consumed in the provision of an intervention or dealing with the side-effects or other current and future consequences linked to it.	Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
Adverse Events 時間枠：Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.	Since this is an observational study there will be no adverse events directly attributable to a study intervention. However, adverse events that might potentially contribute to the risk or course of VAD-related infections will be monitored.	Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Icahn School of Medicine at Mount Sinai

協力者

National Heart, Lung, and Blood Institute (NHLBI)

捜査官

主任研究者：Michael Parides, PhD、Icahn School of Medicine at Mount Sinai
スタディディレクター：Patrice Desvigne-Nickens、National Heart, Lung, and Blood Institute (NHLBI)
スタディチェア：Yoshifumi Naka, MD、Columbia University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2006年1月1日

一次修了 (実際)

2009年1月1日

研究の完了 (実際)